Peptilogics focuses on developing new peptide-based drugs to treat serious infections. The company uses machine learning to enhance its drug design process, allowing for more efficient and precise creation of these therapeutics. Their main product, PLG0206, is currently being tested in clinical trials for treating prosthetic joint infections, which are difficult to manage and have few effective treatments available. What sets Peptilogics apart from other biotechnology firms is its unique combination of peptide biology and advanced technology in drug design. The goal of Peptilogics is to provide effective treatments for patients suffering from life-threatening diseases by advancing the field of peptide therapeutics.

CARB-X

Idea Foundry

Pittsburgh Life Sciences Greenhouse

BlueTree Allied Angels

Stefan Roever

BlueTree Venture Fund

Peter Thiel

Innovation Works

Presight Capital

Founders Fund

AI & Machine Learning

Biotechnology

Healthcare

Peptilogics

Peptilogics receives $3.3 million from CARB-X to develop treatment for fracture-related infections.

Peptilogics receives $3.3 million from CARB-X to develop treatment for fracture-related infections

In both patient cohorts followed for six months after PLG0206 treatment, there were:. No treatment-related serious adverse events and,. No recurrence was observed in 13 of 14 (93%) treated patients at Day-180 in contrast to reported 180-day success rate of 45%

Peptilogics Reports Positive 180-Day Top-Line Interim Data From Phase 1B Trial Of Plg0206 In Patients With Periprosthetic Joint Infection (Pji)

In December 2020, investors from Paypal Holdings Inc. invested US$ 35.4 Mn in US-based biotechnology company Peptilogics Inc.

[Size report] Peptide Therapeutics Market (9.2% CAGR by 2027) to hit $50 billion, globally, with hybrid Technology segment driving growth during 2020-2027 | The Insight Partners

“With PLG0206, Peptilogics is developing a potential curative therapeutic solution for PJI built on its broad spectrum and biofilm-disrupting, anti-microbial properties that lead it to rapidly kill all bacteria living in complex biofilms, including the persister cells that are responsible for resistance to standard antibiotic treatment.

Peptilogics Reports Positive 90-Day Top Line Interim Data From Phase 1b Trial of PLG0206 in Patients with Periprosthetic Joint Infection (PJI) | Peptilogics

Pipeline corner presentation of PLG0206 will be the first glimpse of safety and efficacy data from its ongoing Phase 1b trial in periprosthetic joint infections (PJI)PITTSBURGH--(BUSINESS WIRE)--Peptilogics, a clinical stage biotechnology company, has completed the enrollment of a Phase 1b trial for PLG0206 in patients undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for treatment of a Periprosthetic Joint Infection (PJI) occurring after Total Knee Arthroplasty (TKA). The trial is an open-label dose-escalating study with two dose cohorts of seven patients each compared to historical controls.Peptilogics will present the interim top-line data on PLG0206 from their ongoing Phase 1b trial at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). The presentation will cover clinical safety and tolerability data, alongside reinfection rates for the low dose (3 mg/mL) cohort at the 3-month follow-up highlighting the potent antimicrobial properties of Peptilogics’ engineered peptide PLG0206 for the treatment of periprosthetic joint infection (PJI), a life-threatening complication that patients may develop following joint replacement surgery. In-depth analysis from the low dose cohort along with the readout from the high-dose cohort will be presented at an upcoming conference.“PJI is the last remaining problem in what is otherwise becoming a standard surgery all over the world. More than seven million total joint replacements will be performed annually in the seven major markets by 2030, which will require over 300,000 surgeries per year to try and resolve the infections,” said Jonathan Steckbeck, Chief Executive Officer of Peptilogics. “PJI is an enormous clinical and economic burden on the healthcare system due to the poor outcomes associated with the current standard of care, which includes multiple major surgeries and hospitalizations followed by high doses of antibiotics

Peptilogics Completes Phase 1B Trial Enrollment And Will Present Interim Top-Line Safety And Tolerability Data Of Plg0206 In Patients Undergoing Dair For The Treatment Of Periprosthetic Joint Infection After A Total Knee Arthroplasty At Eccmid 2023

PITTSBURGH--(BUSINESS WIRE)--Peptilogics, a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, today announced that it will host a virtual panel discussion with leading industry experts on the high unmet medical need, economic burden, and opportunity in periprosthetic joint infections (PJI) on Monday, February 27, 2023 at 11 AM ET.The panel discussion moderated by Robin R. Young (Founder  CEO, RRY; Publisher of Orthopedics This Week) will feature Ken Urish, MD, PhD (Associate Professor, University of Pittsburgh Department of Orthopaedic Surgery) and Roshawn Blunt (Health Economist; President, Corsaire Corporation). PJI is the leading cause of failures in total joint arthroplasty and is associated with high morbidity, 5-year mortality of over 20% and the need for complex interdisciplinary treatment strategies. Current standards of care include multiple major surgeries with no curative therapeutic solution, leaving a significant impact on patients’ quality of life. Each surgical treatment of PJI leads to direct hospital costs of over $100,000, adding up close to $500,000 in overall costs per patient to treat PJI. The event will feature a patient’s perspective on the physical and mental burden of PJI and will bring together these expert panelists to discuss the clinical and economic burden on the patients and the overall healthcare system.A live QA session will follow the formal presentations

Peptilogics Hosting Panel Discussion With Leading Industry Experts On The High Unmet Medical Need And Opportunity In Periprosthetic Joint Infections (Pji)

PITTSBURGH--(BUSINESS WIRE)--Peptilogics, a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, is presenting two posters featuring preclinical data from its antimicrobial peptide, PLG0206, at IDWeek 2022. The studies demonstrate the potent activity of PLG0206 against bacteria that cause periprosthetic joint infections (PJI), including multidrug resistant (MDR) bacteria. PJI is the most common complication of joint replacement surgery and is a life-changing event for patients. PJI treatment currently requires an average of three major surgeries per patient, which adds a significant burden on patients, surgeons and the healthcare system. With up to a 60% failure rate and a five-year mortality of 25%, this debilitating condition surpasses the death rates of many cancers. In addition, the increased post-surgical use of standard antibiotics can lead to MDR, a major growing public health concern with few or no therapeutic solutions. MDR related infections pose a significant concern to patients as well as society in both the short- and long-term. These challenges necessitate finding new solutions for treating PJI, including those caused by MDR bacteria. In the data to be presented, PLG0206 demonstrated noteworthy activity against Escherichia coli, Enterobacter cloacae, and Klebsiella pneumoniae, including MDR strains of Gram-negative bacteria that can cause PJI with virtually unchanged minimum inhibitory concentration (MIC)50 or MIC90. Furthermore, PLG0206 demonstrated the most potent antimicrobial activity overall (based on MIC50/90) against enterococci and coagulase-negative staphylococci (CoNS) and showed similar activity to other antibiotics against methicillin-resistant and -sensitive Staphylococcus aureus (MRSA and MSSA). Enterococci, CoNS, and S. aureus are the most common Gram-positive bacteria identified in PJI

Peptilogics To Present Data At Idweek 2022 On Plg0206, An Engineered Antimicrobial Peptide Targeting Bacteria Causing Periprosthetic Joint Infection

PITTSBURGH--(BUSINESS WIRE)--Peptilogics, a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, presented preclinical data from its peptide, PLG0206, at the ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance. Data presented demonstrate activity of PLG0206 against multi-drug resistant pathogens and suggest that this novel antimicrobial peptide could potentially address difficult to treat bacterial infections. The poster, titled “Activity of the novel engineered antimicrobial peptide PLG0206 against non-fermenting Gram-negative rods,” highlights data investigating PLG0206 against isolates Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophili present in skin, urinary, blood, intra-abdominal and respiratory infections. Results demonstrate that PLG0206 was active against all tested isolates and retained activity against multi-drug resistant (MDR) strains, suggesting that the unique mechanism of action of PLG0206 can overcome the drug-resistance mechanisms found in these MDR strains. The poster presented at the joint meeting hosted by the American Society for Microbiology (ASM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) is available on the company website

Peptilogics Presents Data Demonstrating Antimicrobial Activity Against Difficult To Treat Bacterial Pathogens Of Engineered Peptide Plg0206 At The 2022 Asm/Escmid Joint Conference On Drug Development To Meet The Challenge Of Antimicrobial Resistance

PITTSBURGH--(BUSINESS WIRE)--Peptilogics, a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, today announced it has dosed its first patient with PLG0206 in the LOGIC-1 trial for the treatment of periprosthetic joint infections (PJI) occurring after a total knee arthroplasty (TKA). PLG0206 was designed with a unique mechanism of action intended to directly address persistent bacterial pathogens within the biofilm that evade standard of care antibiotics. PLG0206, an investigational product, has been granted FDA Orphan Drug, Fast Track and Qualified Infectious Disease Product (QIDP) Designations for the treatment of PJI. “We are pleased with the dosing of the first patient in the Phase 1b study of our lead peptide candidate, PLG0206, which we believe has the potential improve clinical outcomes for patients suffering and dying from PJIs after a joint replacement. We believe PLG0206 has the potential to change the treatment paradigm for PJI,” said David Huang, M.D., Ph.D, Chief Medical Officer of Peptilogics

Peptilogics Announces First Patient Dosed In Phase 1B Study Of Plg0206 For Periprosthetic Joint Infection

“An AI-driven paradigm shift is happening in drug discovery and EpiAxis is excited to be working with Peptilogics at the forefront of applying AI to the highly valuable space around novel epigenetic targets.”

EpiAxis Therapeutics Pty partners with Peptilogics

Develops peptide therapeutics using machine learning

Peptilogics

Develops peptide therapeutics using machine learning

Peptilogics

Develops peptide therapeutics using machine learning

About

Simplify's Take

What believers are saying

What critics are saying

What makes Peptilogics unique

6 month growth

1 year growth

2 year growth

Benefits

Recently Posted Jobs

There are no jobs for Peptilogics right now.